BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30597637)

  • 1. Production of a novel N-terminal PEGylated crisantaspase.
    Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
    Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel site-specific PEGylated L-asparaginase.
    Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase.
    Torres-Obreque K; Kleingesinds EK; Santos JHPM; Carretero G; Rabelo J; Converti A; Monteiro G; Pessoa A; Rangel-Yagui CO
    Prep Biochem Biotechnol; 2024 Apr; 54(4):503-513. PubMed ID: 37698175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
    Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
    Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte.
    Kurinomaru T; Shiraki K
    J Pharm Sci; 2015 Feb; 104(2):587-92. PubMed ID: 25354692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PEGylation technology of L-asparaginase with monomethoxy polyethylene glycol-propionaldehyde.
    Wang B; Cao Y; Chi S; Lou D
    Z Naturforsch C J Biosci; 2012; 67(5-6):312-8. PubMed ID: 22888537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
    Modi T; Gervais D
    Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase.
    Soares AL; Guimarães GM; Polakiewicz B; de Moraes Pitombo RN; Abrahão-Neto J
    Int J Pharm; 2002 Apr; 237(1-2):163-70. PubMed ID: 11955814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase activities during intensified treatment with pegylated
    Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
    Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials.
    Viña-Romero MM; Ramos Díaz R; González García J; Nazco-Casariego G; Díaz-Vera J; Gutiérrez-Nicolás F
    J Oncol Pharm Pract; 2021 Jul; 27(5):1102-1105. PubMed ID: 32854574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
    Schnuchel A; Radcke C; Theobald L; Doeding S
    PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Cell-Free Protein Synthesis for High-Yield Production and Human Serum Activity Assessment of Asparaginase: Toward On-Demand Treatment of Acute Lymphoblastic Leukemia.
    Hunt JP; Wilding KM; Barnett RJ; Robinson H; Soltani M; Cho JE; Bundy BC
    Biotechnol J; 2020 Apr; 15(4):e1900294. PubMed ID: 31904183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.